MARKET

GOVX

GOVX

Geovax Labs Inc
NASDAQ
0.2070
+0.0360
+21.05%
After Hours: 0.1900 -0.017 -8.21% 19:58 01/02 EST
OPEN
0.1770
PREV CLOSE
0.1710
HIGH
0.2105
LOW
0.1770
VOLUME
6.57M
TURNOVER
--
52 WEEK HIGH
2.750
52 WEEK LOW
0.1151
MARKET CAP
8.96M
P/E (TTM)
-0.1053
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at GOVX last week (1222-1226)?
Weekly Report · 12/29/2025 09:37
GeoVax Labs Announces Public Equity Offering for Liquidity
TipRanks · 12/22/2025 22:02
Weekly Report: what happened at GOVX last week (1215-1219)?
Weekly Report · 12/22/2025 09:37
12 Health Care Stocks Moving In Friday's Intraday Session
Benzinga · 12/19/2025 17:05
Dow Gains Over 200 Points; Conagra Shares Fall After Q2 Results
Benzinga · 12/19/2025 15:09
Weekly Report: what happened at GOVX last week (1208-1212)?
Weekly Report · 12/15/2025 09:40
GeoVax Labs Files Prospectus For Best-Efforts Offering Of 18,292,683 Units And Pre-Funded Units With Warrants
Benzinga · 12/12/2025 22:42
*GeoVax Labs Offering 18.3M Units, Each Consisting of One Share and Two Warrants; Certain Investors May Choose Pre-Funded Units in Lieu of Common Units
Dow Jones · 12/12/2025 22:39
More
About GOVX
GeoVax Labs, Inc. is a clinical-stage biotechnology company developing human vaccines and immunotherapies against infectious diseases and solid tumor cancers using proprietary platforms. Its product pipeline includes ongoing human clinical trials for a Covid-19 vaccine and a gene-directed therapy against advanced head and neck cancers. Its additional research and development programs include preventive vaccines against Mpox and smallpox, hemorrhagic fever viruses (Ebola Zaire, Ebola Sudan and Marburg), Zika virus and malaria, as well as immunotherapies for multiple solid tumors. The Company’s portfolio of wholly owned, co-owned, and in-licensed intellectual property, stands at over 155 granted or pending patent applications spread over 24 patent families. Its product candidate includes GEO-CM04S1, GEO-CM02, Gedeptin, MVA-VLP-MUC1, GEO-ZM02 and others. Its lead infectious disease candidate is GEO-CM04S1, a COVID-19 vaccine targeting high-risk immunocompromised patient populations.

Webull offers Geovax Labs Inc stock information, including NASDAQ: GOVX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, GOVX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading GOVX stock methods without spending real money on the virtual paper trading platform.